HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer


Condition: Prostate Cancer

Intervention:

  • Drug: Relugolix
  • Drug: Leuprolide Acetate

Purpose: The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (≤ 50 ng/dL [1.7 nmol/L] in patients with androgen-sensitive advanced prostate cancer.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03085095

Sponsor: Myovant Sciences GmbH

Primary Outcome Measures:

  • Measure: Sustained Castration Rate
  • Time Frame: 48 weeks
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Castration Rate by Visit
  • Time Frame: up to 3 weeks
  • Safety Issue:
  • Measure: Profound Castration Rate
  • Time Frame: up to 48 weeks
  • Safety Issue:
  • Measure: Prostate-specific antigen (PSA) response rate by PCWG3 criteria
  • Time Frame: at 3 weeks and at 5 weeks
  • Safety Issue:
  • Measure: PSA response rate
  • Time Frame: at 3 weeks and at 5 weeks
  • Safety Issue:
  • Measure: Time to PSA progression
  • Time Frame: up to 48 weeks
  • Safety Issue:
  • Measure: Quality of life (QoL) total score and each subdomain score
  • Time Frame: up to 48 weeks
  • Safety Issue:
  • Measure: Time to castration resistance
  • Time Frame: up to 48 weeks
  • Safety Issue:
  • Measure: Composite of safety as measure of safety and tolerability
  • Time Frame: up to 48 weeks
  • Safety Issue:
  • Measure: Pharmacokinetics of relugolix
  • Time Frame: up to 52 weeks
  • Safety Issue:
  • Measure: Serum concentrations of luteinizing hormone, follicle-stimulating hormone, dihydrotestosterone, sex hormone binding globulin
  • Time Frame: up to 24 weeks
  • Safety Issue:
  • Measure: Testosterone recovery
  • Time Frame: up to 90 days after end of study treatment
  • Safety Issue:

Estimated Enrollment: 1100

Study Start Date: April 18, 2017

Phase: Phase 3

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Key Inclusion Criteria:

  1. Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;
  2. Is a candidate for, in the opinion of the investigator, at least 1 year of continuous androgen deprivation therapy for the management of androgen-sensitive advanced prostate cancer with one of the following clinical disease state presentations:
  3. Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery; or
  4. Newly diagnosed androgen-sensitive metastatic disease; or
  5. Advanced localized disease unlikely to be cured by local primary intervention with either surgery or radiation with curative intent Note: Once 915 patients are enrolled worldwide only patients with metastatic advanced prostate cancer will be eligible for the study in all regions except China, where both metastatic and non-metastatic patients will continue to be enrolled.
  6. Has a serum testosterone at the Screening visit of ≥ 150 ng/dL (5.2 nmol/L);
  7. Has a serum PSA concentration at the Screening visit of > 2.0 ng/mL (2.0 μg/L), or, when applicable, post radical prostatectomy of > 0.2 ng/mL (0.2 μg/L) or post radiotherapy, cryotherapy, or high frequency ultrasound > 2.0 ng/mL (2.0 μg/L) above the post interventional nadir;
  8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at initial screening and at baseline.

Key Exclusion Criteria:

  1. In the investigator's opinion, is likely to require chemotherapy or surgical therapy for symptomatic disease management within 2 months of initiating androgen deprivation therapy;
  2. Previously received GnRH analog or other form of androgen deprivation therapy (estrogen or antiandrogen) for > 18 months total duration. If androgen deprivation therapy was received for ≤ 18 months total duration, then that therapy must have been completed at least 3 months prior to baseline. If the dosing interval of the depot is longer than 3 months, then the prior androgen deprivation therapy must have been completed at least as long as the dosing interval of the depot;
  3. Previous systemic cytotoxic treatment for prostate cancer (eg: taxane-based regimen);
  4. Metastases to brain per prior clinical evaluation;
  5. Scheduled for major surgery after baseline;
  6. History of surgical castration.

Contact:

  • Clinical Trials at Myovant
  • 650-278-8743

Locations:

  • Homewood
  • Homewood Alabama 35209 United States
  • Anchorage
  • Anchorage Alaska 99503 United States
  • Tucson
  • Tucson Arizona 85741 United States
  • Orange
  • Orange California 92868 United States
  • San Diego
  • San Diego California 92120 United States
  • Denver
  • Denver Colorado 80211 United States
  • Pompano Beach
  • Pompano Beach Florida 33060 United States
  • Jeffersonville
  • Jeffersonville Indiana 47130 United States
  • Des Moines
  • Des Moines Iowa 50266 United States
  • Wichita
  • Wichita Kansas 67226 United States
  • Towson
  • Towson Maryland 21204 United States
  • Troy
  • Troy Michigan 48084 United States
  • Omaha
  • Omaha Nebraska 68130 United States
  • Las Vegas
  • Las Vegas Nevada 89135 United States
  • Brick
  • Brick New Jersey 08724 United States
  • Lawrenceville
  • Lawrenceville New Jersey 08648 United States
  • Albuquerque
  • Albuquerque New Mexico 87109 United States
  • Albany
  • Albany New York 12208 United States
  • Brooklyn
  • Brooklyn New York 11215 United States
  • Garden City
  • Garden City New York 11530 United States
  • New York
  • New York New York 10029 United States
  • Plainview
  • Plainview New York 11803 United States
  • Poughkeepsie
  • Poughkeepsie New York 12601 United States
  • Syracuse
  • Syracuse New York 13210 United States
  • Durham
  • Durham North Carolina 27710 United States
  • Greensboro
  • Greensboro North Carolina 27403 United States
  • Winston-Salem
  • Winston-Salem North Carolina 27157 United States
  • Cincinnati
  • Cincinnati Ohio 45212 United States
  • MiddleBurg Heights
  • Middleburg Heights Ohio 44130 United States
  • Toledo
  • Toledo Ohio 43614 United States
  • Oklahoma City
  • Oklahoma City Oklahoma 73104 United States
  • Lancaster
  • Lancaster Pennsylvania 17604 United States
  • Myrtle Beach
  • Myrtle Beach South Carolina 29572 United States
  • Nashville
  • Nashville Tennessee 37209 United States
  • Dallas
  • Dallas Texas 75231 United States
  • San Antonio
  • San Antonio Texas 78229 United States
  • Virginia Beach
  • Virginia Beach Virginia 23462 United States
  • Camperdown
  • Camperdown New South Wales 2050 Australia
  • Darlinghurst
  • Darlinghurst New South Wales 2010 Australia
  • Tweed Heads
  • Tweed Heads New South Wales 2485 Australia
  • Wahroonga
  • Wahroonga New South Wales 2076 Australia
  • Westmead
  • Westmead New South Wales 2145 Australia
  • Cairns
  • Cairns Queensland 4870 Australia
  • Redcliffe
  • Redcliffe Queensland 4020 Australia
  • Geelong
  • Geelong Victoria 3220 Australia
  • Herston
  • Herston Australia
  • Linz
  • Linz A-4010 Austria
  • Salzburg
  • Salzburg 5020 Austria
  • Edegem
  • Edegem Antwerpen 2650 Belgium
  • Gent
  • Gent Oost-Vlaanderen 9000 Belgium
  • Leuven
  • Leuven Vlaams Brabant 3000 Belgium
  • Brussels
  • Brussels 1200 Belgium
  • Kortrijk
  • Kortrijk 8500 Belgium
  • Itabuna
  • Itabuna Bahia 45602 Brazil
  • Salvador
  • Salvador Bahia 40050 Brazil
  • Salvador
  • Salvador Bahia 41820 Brazil
  • Curitiba
  • Curitiba Paraná 80530 Brazil
  • Teresina
  • Teresina Piauí 64001 Brazil
  • Natal
  • Natal Rio Grande Do Norte 59062 Brazil
  • Ijuí
  • Ijuí Rio Grande Do Sul 98700 Brazil
  • Passo Fundo
  • Passo Fundo Rio Grande Do Sul 99010-260 Brazil
  • Porto Alegre
  • Porto Alegre Rio Grande Do Sul 90035-903 Brazil
  • Porto Alegre
  • Porto Alegre Rio Grande Do Sul 90110-270 Brazil
  • Porto Alegre
  • Porto Alegre Rio Grande Do Sul 90430-090 Brazil
  • Porto Alegre
  • Porto Alegre Rio Grande Do Sul 90610 Brazil
  • Joinville
  • Joinville Santa Catarina 89201 Brazil
  • São José Do Rio Preto
  • São José Do Rio Preto Sao Paulo 15090 Brazil
  • São Paulo
  • São Paulo 01406 Brazil
  • Calgary
  • Calgary Alberta T2V1P9 Canada
  • Vancouver
  • Vancouver British Columbia V5Z1M9 Canada
  • Halifax
  • Halifax Nova Scotia B3H2Y9 Canada
  • Hamilton
  • Hamilton Ontario L8N4A6 Canada
  • London
  • London Ontario N6A5W9 Canada
  • Montreal
  • Montréal Quebec H2X0A9 Canada
  • Sherbrooke
  • Sherbrooke Quebec J1H5N4 Canada
  • Toronto
  • Toronto Quebec H2X0A9 Canada
  • Quebec
  • Quebec Canada
  • Nanjing
  • Nanjing Jiangsu 210008 China
  • Changchun
  • Chang chun Jilin 130021 China
  • Shanghai
  • Shanghai Shanghai 020043 China
  • Taiyuan
  • Taiyuan Shanxi 030001 China
  • Beijing
  • Beijing 100050 China
  • Chongqing
  • Chongqing 400030 China
  • Lanzhou
  • Lanzhou 730030 China
  • Shanghai
  • Shanghai 200040 China
  • Alborg
  • Aalborg Nordjylland DK-9000 Denmark
  • Aarhus
  • Aarhus 8200 Denmark
  • Copenhagen
  • Copenhagen 2200 Denmark
  • Herlev
  • Herlev 2730 Denmark
  • Vejle
  • Vejle DK-7100 Denmark
  • Helsinki
  • Helsinki 00029 HUS Finland
  • Seinajoki
  • Seinäjoki FI-60220 Finland
  • Tampere
  • Tampere FI-33520 Finland
  • Turku
  • Turku FI-20520 Finland
  • Strasbourg
  • Strasbourg Bas-Rhin 67091 France
  • Marseille
  • Marseille Bouches-du-Rhône 13385 France
  • Lille
  • Lille Nord 59037 France
  • Pierre Benite
  • Pierre-Bénite Rhone 69495 France
  • Creteil
  • Créteil Val De Marne 94010 France
  • Creteil
  • Créteil Val-de-Marne 94010 France
  • Hyeres
  • Hyères 83400 France
  • Lyon
  • Lyon 69437 France
  • Nimes
  • Nîmes 30029 France
  • Poitiers
  • Poitiers 86021 France
  • Emmendingen
  • Emmendingen Baden-Wurttemberg 79312 Germany
  • Planegg
  • Planegg Bayern 82152 Germany
  • Braunschweig
  • Braunschweig Niedersachsen 38100 Germany
  • Braunschweig
  • Braunschweig Niedersachsen 38126 Germany
  • Dresden
  • Dresden 01307 Germany
  • Hamburg
  • Hamburg 22399 Germany
  • Lubeck
  • Lübeck 23538 Germany
  • Munster
  • Münster 48149 Germany
  • Meldola
  • Meldola Emilia-Romagna 47014 Italy
  • Rome
  • Rome Lazio 00152 Italy
  • Cremona
  • Cremona Lombardia 26100 Italy
  • Candiolo
  • Candiolo Piemonte 10060 Italy
  • Orbassano
  • Orbassano Piemonte 10043 Italy
  • Arezzo
  • Arezzo Toscana 52100 Italy
  • Milano
  • Milano 20162 Italy
  • Pavia
  • Pavia 27100 Italy
  • Kanazawa-shi
  • Kanazawa-shi Isikawa 920-8641 Japan
  • Sendai
  • Sendai Miyagi 9808574 Japan
  • Sendai
  • Sendai Miyagi 9818563 Japan
  • Suita
  • Suita Osaka 565-0871 Japan
  • Osaka-sayama City
  • Ōsaka-sayama Osaka 589-8511 Japan
  • Fukuoka
  • Fukuoka 812-0033 Japan
  • Hiroshima
  • Hiroshima 730-8518 Japan
  • Hiroshima
  • Hiroshima 7308518 Japan
  • Kita-gun
  • Kita 761093 Japan
  • Kyoto
  • Kyoto 606-8507 Japan
  • Maebashi-shi
  • Maebashi 371-8511 Japan
  • Nagasaki-shi
  • Nagasaki Japan
  • Osaka
  • Osaka Japan
  • Sapporo
  • Sapporo 003-0804 Japan
  • Tokyo
  • Tokyo 285-8741 Japan
  • Tokyo
  • Tokyo Japan
  • Ube-shi
  • Ube 7558505 Japan
  • Yokohama City
  • Yokohama Japan
  • Ōsaka-sayama
  • Ōsaka-sayama Ôsaka 589-8511 Japan
  • Goyang-Si
  • Goyang-si Gyeonggido 10408 Korea, Republic of
  • Busan
  • Busan 49241 Korea, Republic of
  • Hwasun-gun
  • Hwasun 58128 Korea, Republic of
  • Hwasun-gun
  • Hwasun Korea, Republic of
  • Seongnam
  • Seongnam 13620 Korea, Republic of
  • Seoul
  • Seoul 03722 Korea, Republic of
  • Seoul
  • Seoul 05505 Korea, Republic of
  • Seoul
  • Seoul 06351 Korea, Republic of
  • Seoul
  • Seoul 135720 Korea, Republic of
  • Seoul
  • Seoul 13572 Korea, Republic of
  • Eindhoven
  • Eindhoven Noord Brabant 5623EJ Netherlands
  • Amsterdam
  • Amsterdam Noord Holland 1105AZ Netherlands
  • Maastricht
  • Maastricht 6229HX Netherlands
  • Sneek
  • Sneek 8601 ZK Netherlands
  • Hamilton
  • Hamilton Northland 3204 New Zealand
  • Dunedin
  • Dunedin South Island 9001 New Zealand
  • Canterbury
  • Christchurch 8013 New Zealand
  • Tauranga
  • Tauranga 3140 New Zealand
  • Wroclaw
  • Wrocław Dolnoslaskie 53114 Poland
  • Gdynia
  • Gdynia Lubelskie 20-582 Poland
  • Lublin
  • Lublin Lubelskie 20582 Poland
  • Siedlce
  • Siedlce Mazowieckie 08110 Poland
  • Warszawa
  • Warszawa Mazowieckie 02-797 Poland
  • Gdynia
  • Gdynia 81-519 Poland
  • Gdynia
  • Gdynia 81519 Poland
  • Katowice
  • Katowice 40611 Poland
  • Bratislava
  • Bratislava 845 05 Slovakia
  • Kosice
  • Košice 04001 Slovakia
  • Martin
  • Martin Slovakia
  • Nitra
  • Nitra 94901 Slovakia
  • Poprad
  • Poprad Slovakia
  • Presov
  • Prešov 080 01 Slovakia
  • Trencin
  • Trenčín 911 01 Slovakia
  • Sula
  • Šula 927 01 Slovakia
  • A Coruna
  • A Coruña A Coruna 15006 Spain
  • Oviedo
  • Oviedo Asturias 33011 Spain
  • Barcelona
  • Barcelona 8036 Spain
  • Barcelona
  • Barcelona Spain
  • Madrid
  • Madrid 28006 Spain
  • Madrid
  • Madrid 28041 Spain
  • Sabadell
  • Sabadell 08208 Spain
  • Salamanca
  • Salamanca 37007 Spain
  • Santiago de Compostela
  • Santiago de Compostela 15706 Spain
  • Valencia
  • Valencia 46009 Spain
  • Orebro
  • Örebro Orebro Ian SE-70185 Sweden
  • Malmo
  • Malmö Skane Ian Sweden
  • Stockholm
  • Stockholm Sodermandlands Ian Sweden
  • Stockholm
  • Stockholm Sodermanlands Ian Sweden
  • Uppsala
  • Uppsala 751 85 Sweden
  • Kaohsiung
  • Kaohsiung Taiwan
  • Taipei
  • Taipei 112 Taiwan
  • Taipei
  • Taipei 11490 Taiwan
  • Taipei
  • Taipei Taiwan
  • Wirral
  • Wirral Cheshire CH63 4JY United Kingdom
  • Glasgow
  • Glasgow Glasgow City G12 0YN United Kingdom
  • Scunthorpe
  • Scunthorpe North Lincolnshire DN157BH United Kingdom
  • Aberdeen
  • Aberdeen AB252ZN United Kingdom
  • Nottingham
  • Nottingham NG5 1PB United Kingdom
  • Plymouth
  • Plymouth PL68DH United Kingdom
  • Wrexham
  • Wrexham United Kingdom

View trial on ClinicalTrials.gov


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe